Charles Sternberg, Associate Editor05.05.23
Dexcom Inc., a global leader in continuous glucose monitoring for people with diabetes, plans to build its newest global manufacturing facility in Athenry, Galway.
The project is supported by the Irish Government through IDA Ireland and represents an investment of €300 million over five years and the potential to create up to 1,000 high skilled jobs over the same period.
In addition to the thousand jobs being created by the company, it will bring many spin-off opportunities, jobs and contracts for other businesses in the region.
Attending the event, Minister for Enterprise Trade & Employment Simon Coveney TD said: “I am delighted that Dexcom has chosen to make this major new investment in Ireland. It’s a huge vote of confidence in Ireland’s significant and growing talent pool and the world-class MedTech cluster that has developed in the West of the country. The very substantial employment opportunities that accompany the arrival of Dexcom in Athenry will be a considerable boost to the West MidWest and Midlands regions.”
Subject to planning permission, the Ireland site will be Dexcom’s first manufacturing site in Europe, expanding upon the company’s existing capabilities in the U.S. and Malaysia. The new facility will have the capacity to produce millions of Dexcom CGM sensors each year, helping to improve the lives of people with diabetes around the world. Subject to planning approval, the new facility will be located on the IDA Ireland strategic landbank in Athenry.
The facility in Athenry will contain a highly automated and efficient manufacturing operation with an emphasis on green technologies. Dexcom expects to provide about 500 construction jobs while the facility is being built and up to 1,000 high tech graduate and technician level positions once the site is running at full capacity.
“With the continued success of our Dexcom G7 in Europe, we are pursuing an ambitious growth strategy that requires increased manufacturing capacity to support our rapidly expanding European user base,” said Barry Regan, Executive Vice President of Global Operations at Dexcom. “Ireland has an exceptional talent pool and an established MedTech sector, making Athenry the perfect location for us to establish a new, state-of-the-art manufacturing facility.”
In October 2022, Ireland was one of the initial launch markets globally for Dexcom G7, the company’s next-generation CGM system that helps people gain greater control of their diabetes. Dexcom G7 builds on the trusted performance of Dexcom CGM, which is clinically proven to lower A1C and reduce hyper- and hypoglycemia.
The project is supported by the Irish Government through IDA Ireland and represents an investment of €300 million over five years and the potential to create up to 1,000 high skilled jobs over the same period.
In addition to the thousand jobs being created by the company, it will bring many spin-off opportunities, jobs and contracts for other businesses in the region.
Attending the event, Minister for Enterprise Trade & Employment Simon Coveney TD said: “I am delighted that Dexcom has chosen to make this major new investment in Ireland. It’s a huge vote of confidence in Ireland’s significant and growing talent pool and the world-class MedTech cluster that has developed in the West of the country. The very substantial employment opportunities that accompany the arrival of Dexcom in Athenry will be a considerable boost to the West MidWest and Midlands regions.”
Subject to planning permission, the Ireland site will be Dexcom’s first manufacturing site in Europe, expanding upon the company’s existing capabilities in the U.S. and Malaysia. The new facility will have the capacity to produce millions of Dexcom CGM sensors each year, helping to improve the lives of people with diabetes around the world. Subject to planning approval, the new facility will be located on the IDA Ireland strategic landbank in Athenry.
The facility in Athenry will contain a highly automated and efficient manufacturing operation with an emphasis on green technologies. Dexcom expects to provide about 500 construction jobs while the facility is being built and up to 1,000 high tech graduate and technician level positions once the site is running at full capacity.
“With the continued success of our Dexcom G7 in Europe, we are pursuing an ambitious growth strategy that requires increased manufacturing capacity to support our rapidly expanding European user base,” said Barry Regan, Executive Vice President of Global Operations at Dexcom. “Ireland has an exceptional talent pool and an established MedTech sector, making Athenry the perfect location for us to establish a new, state-of-the-art manufacturing facility.”
In October 2022, Ireland was one of the initial launch markets globally for Dexcom G7, the company’s next-generation CGM system that helps people gain greater control of their diabetes. Dexcom G7 builds on the trusted performance of Dexcom CGM, which is clinically proven to lower A1C and reduce hyper- and hypoglycemia.
